Targeted attack: mechanisms by which ovarian cancers suppress the immune system

Tiper, Irina V.; Webb, Tonya J.

doi:10.21037/tcr.2016.11.62

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Experimental research has shown that the administration of bevacizumab can reverse the maturation defect of DCs [ 48 ]. In OC cell lines, the inhibition of VEGF production leads to a reduction in the expression of the immunosuppressive ganglioside GD3 and the activation of NK T cells [ 49 ]. In addition, blocking VEGF can transiently normalize the tortuous vasculature of the tumor, reducing hypoxia and allowing greater infiltration of immune cells (Fig.…”

Section: Biological Rationale For the Antiangiogenic-immunotherapy Comentioning

confidence: 99%

Are antiangiogenics a good ‘partner’ for immunotherapy in ovarian cancer?

et al. 2020

View full text Add to dashboard Cite

Ovarian cancer (OC) is associated with poor survival because there are a limited number of effective therapies. Two processes key to OC progression, angiogenesis and immune evasion, act synergistically to promote tumor progression. Tumor-associated angiogenesis promotes immune evasion, and tumor-related immune responses in the peritoneal cavity and tumor microenvironment (TME) affect neovascular formation. Therefore, suppressing the angiogenic pathways could facilitate the arrival of immune effector cells and reduce the presence of myeloid cells involved in immune suppression. To date, clinical studies have shown significant benefits with antiangiogenic therapy as first-line therapy in OC, as well as in recurrent disease, and the vascular endothelial growth factor (VEGF) inhibitor bevacizumab is now an established therapy. Clinical data with immunomodulators in OC are more limited, but suggest that they could benefit some patients with recurrent disease. The preliminary results of two phase III trials have shown that the addition of immunomodulators to chemotherapy does not improve progression-free survival. For this reason, it could be interesting to look for synergistic effects between immunomodulators and other active drugs in OC. Since bevacizumab is approved for use in OC, and is tolerable when used in combination with immunotherapy in other indications, a number of clinical studies are underway to investigate the use of bevacizumab in combination with immunotherapeutic agents in OC. This strategy seeks to normalize the TME via the anti-VEGF actions of bevacizumab, while simultaneously stimulating the immune response via the immunotherapy. Results of these studies are awaited with interest.

show abstract

Section: Biological Rationale For the Antiangiogenic-immunotherapy Comentioning

confidence: 99%